CatalYm
Latest round
- Series D
Last raised
- Jul 2024
Total raised
- $261M
Investors
- 14
About CatalYm
Founded in 2016, CatalYm GmbH is dedicated to developing therapies that target GDF-15, a key protein involved in cancer treatment resistance.000 mn.CatalYm focuses on the development of innovative immunotherapy solutions that specifically target GDF-15 to counteract resistance to cancer therapies. Its flagship product, Visugromab, functions as a monoclonal antibody designed to neutralize GDF-15, thus reinstating effective anti-tumor immune responses in patients with solid tumors. This treatment addresses immune suppression in cancer patients who have not responded to prior therapies, particularly for those resistant to checkpoint inhibitors.CatalYm's revenue model is built on partnerships and collaborations within the pharmaceutical and biotech sectors, particularly around the clinical development of its lead product, Visugromab. The company collaborates with healthcare institutions, research organizations, and industry partners to facilitate clinical trials and the commercialization of its therapies.CatalYm GmbH aims to expand its product portfolio with new therapies targeting GDF-15 and anticipates launching additional products in the coming years. The company is also exploring expansion into new geographic markets, particularly targeting regions in Europe and North America.
Who invested in CatalYm
14 investors across 4 rounds
See all investors in CatalYm
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about CatalYm
Who invested in CatalYm?
CatalYm has 14 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has CatalYm raised?
CatalYm has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did CatalYm last raise money?
CatalYm's most recent round on record is a Series D, in Jul 2024.
What does CatalYm do?
Founded in 2016, CatalYm GmbH is dedicated to developing therapies that target GDF-15, a key protein involved in cancer treatment resistance.
Where is CatalYm headquartered?
CatalYm is headquartered in Germany.
Which VCs invest in companies like CatalYm?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at CatalYm's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like CatalYm? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.